UOC
CLVS

UBS O'Connor’s Clovis Oncology, Inc. CLVS Stock Holding History

UBS O'Connor’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-20,000
Closed -$1.21M – 536
2013
Q4 		$1.21M Buy
+20,000
New +$1.09M 0.02% 288

Other funds holding CLVS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
CPCM
Clifton Park Capital Management Wilmington, Delaware $881M AUM 5.59% 1-Year Est. Return

UBS O'Connor's CLVS Position: Q1 2014 in Review

UBS O'Connor sold out of Clovis Oncology, Inc. (CLVS) in Q1 2014, closing a stake of 20,000 shares — an estimated $1.21M sold.

UBS O'Connor first reported a position in CLVS in Q4 2013 and held it in 1 quarter. The position peaked at $1.21M in Q4 2013. 137 funds tracked by Wall St. Rank hold CLVS as of Q1 2014.

  • UBS O'Connor reported no remaining Clovis Oncology, Inc. position as of Q1 2014 after selling out during the quarter.
  • UBS O'Connor sold 20,000 Clovis Oncology, Inc. shares in Q1 2014, an estimated $1.21M.
  • UBS O'Connor first reported a position in Clovis Oncology, Inc. in Q4 2013 and held it in 1 quarter.
  • UBS O'Connor's Clovis Oncology, Inc. position peaked at $1.21M in Q4 2013.
  • 137 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q1 2014.

Based on UBS O'Connor's 13F filing for Q1 2014, filed 14 May 2014.